Wednesday, November 18, 2026·Focal News

Focal News

Independent local reporting across America

Politics

White House withdraws FDA nominee Heidi Overton ahead of key Senate committee vote

The Trump administration pulled Heidi Overton's nomination to lead the FDA late Tuesday, citing insufficient Republican support on the Senate health panel. The move came hours before a scheduled committee vote and followed scrutiny over her evasiveness on abortion pill regulation and political independence.

White House withdraws FDA nominee Heidi Overton ahead of key Senate committee vote

WASHINGTON — The White House withdrew Heidi Overton's nomination to head the Food and Drug Administration on Tuesday night, hours before the Senate Health, Education, Labor and Pensions Committee was set to vote on her confirmation, according to a White House official.

The decision to pull the nomination came after several Republican senators on the panel signaled they were not ready to support Overton, a White House health policy aide who testified before the committee in September. A White House official confirmed the withdrawal, speaking on condition of anonymity to discuss the decision.

Overton's nomination had drawn quiet but growing skepticism from key Republicans even before her September hearing. During that session, she declined to say how she would regulate abortion pills if confirmed, and she sidestepped questions about how she would maintain independence from political pressure at the public health agency. She did, however, publicly affirm the safety and efficacy of the measles, mumps and rubella vaccine — a notable stance given President Donald Trump's past statements suggesting the shot is dangerous.

Several GOP senators told reporters this week they remained undecided on Overton's nomination, and the committee vote scheduled for Wednesday morning was widely seen as a test of her support. The withdrawal avoids what could have been an embarrassing defeat for the administration on a high-profile health post.

The nomination also became entangled in internal tensions over Health Secretary Robert F. Kennedy Jr.'s "Make America Healthy Again" agenda. Former Trump administration aide Calley Means publicly accused Overton of undermining that agenda, specifically linking her to efforts to shield pesticide manufacturers from liability claims and to block psychedelic treatments from advancing toward FDA approval.

The FDA has been without a Senate-confirmed commissioner for much of the year, and the withdrawal leaves the agency without a permanent leader as it navigates a range of public health challenges, from vaccine policy to drug approvals. It was not immediately clear whom the White House might nominate next, or when a new pick would be announced.

The committee had been scheduled to vote at 10 a.m. Wednesday. Overton's nomination is now effectively dead, and the administration will have to restart the search for a candidate who can win confirmation in a narrowly divided Senate.

More from Focal News